Cargando…

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks

BACKGROUND: The aim of this multicenter, randomized, double-blind study was to examine the effect of lobeglitazone, a novel thiazolidinedione, on the changes in bone mineral density (BMD) in patients with type 2 diabetes mellitus. METHODS: A 24-week, double-blinded phase was followed by a 28-week, o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Soo, Kim, Kyoung Min, Kim, Sin Gon, Kim, Doo Man, Woo, Jeong-Taek, Chung, Choon Hee, Ko, Kyung Soo, Park, Jeong Hyun, Park, Yongsoo, Kim, Sang Jin, Jang, Hak Chul, Choi, Dong Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663677/ https://www.ncbi.nlm.nih.gov/pubmed/29086536 http://dx.doi.org/10.4093/dmj.2017.41.5.377

Ejemplares similares

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
por: Kim, Sin Gon, et al.
Publicado: (2014)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
por: Kim, Kyoung Min, et al.
Publicado: (2017)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects
por: Kim, Heeyoung, et al.
Publicado: (2023)

Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
por: Lee, Da Young, et al.
Publicado: (2017)

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
por: Yoo, Joonsang, et al.
Publicado: (2023)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
por: Shin, Na-Rae, et al.
Publicado: (2018)

Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
por: Lee, Yong-ho, et al.
Publicado: (2017)

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
por: Kim, Kyung-Soo, et al.
Publicado: (2020)

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice
por: Choung, Sorim, et al.
Publicado: (2018)

A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
por: Kim, Bo-Yeon, et al.
Publicado: (2022)

Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
por: Jung, Jin Ah, et al.
Publicado: (2015)

Lobeglitazone Exerts Anti-Inflammatory Effect in Lipopolysaccharide-Induced Bone-Marrow Derived Macrophages
por: Jeong, Dabin, et al.
Publicado: (2021)

Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study
por: Lim, Soo, et al.
Publicado: (2020)

Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice
por: Choi, Bong-Hoi, et al.
Publicado: (2018)

Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ
por: Jang, Jun Young, et al.
Publicado: (2018)

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea
por: Kim, Hye-soon, et al.
Publicado: (2014)

Lobeglitazone inhibits LPS-induced NLRP3 inflammasome activation and inflammation in the liver
por: Seo, Hye-Young, et al.
Publicado: (2023)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
por: Lee, Yu Seol, et al.
Publicado: (2018)

A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
por: Ryang, Soree, et al.
Publicado: (2022)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
por: Lee, Kyeong Won, et al.
Publicado: (2011)

Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
por: Ko, Ki Dong, et al.
Publicado: (2017)

Effect of the Algicide Thiazolidinedione 49 on Immune Responses of Bay Scallop Argopecten Irradians
por: Chi, Cheng, et al.
Publicado: (2019)

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
por: Park, Min Jeong, et al.
Publicado: (2023)

Hydroxyapatite Mineralization on the Calcium Chloride Blended Polyurethane Nanofiber via Biomimetic Method
por: Nirmala, R, et al.
Publicado: (2010)

Klebsiella pneumoniae Orbital Cellulitis with Extensive Vascular Occlusions in a Patient with Type 2 Diabetes
por: Yang, Sae Jeong, et al.
Publicado: (2010)

Effects of Three Thiazolidinediones on Metabolic Regulation and Cold-Induced Thermogenesis
por: Sohn, Jee Hyung, et al.
Publicado: (2018)

Evaluation of 2-week repeated oral dose toxicity of 100 nm zinc oxide nanoparticles in rats
por: Ko, Je-Won, et al.
Publicado: (2015)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
por: Bae, Kwi-Hyun, et al.
Publicado: (2017)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
por: Sharma, Chiranjeev, et al.
Publicado: (2019)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
por: Ahn, Chang Ho, et al.
Publicado: (2019)

Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes
por: Lee, Mi Young, et al.
Publicado: (2008)

Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient‐ and physician‐related factors): A prospective observational DIPP‐FACTOR study in Korea
por: Kim, Sin Gon, et al.
Publicado: (2017)

Detoxification, Apoptosis, and Immune Transcriptomic Responses of the Gill Tissue of Bay Scallop Following Exposure to the Algicide Thiazolidinedione 49
por: Chi, Cheng, et al.
Publicado: (2019)

Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation
por: Lee, Ji-Yeon, et al.
Publicado: (2018)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Changes in body weight and food security of adult North Korean refugees living in South Korea
por: Jeong, HaYoung, et al.
Publicado: (2017)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
por: Kim, Yu Kyong, et al.
Publicado: (2021)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rv2rqsks4ir26sa8hb4v75o43n